frequenc
moder
sever
advers
reaction
associ
smallpox
vaccin
current
stockpil
us
continu
threat
bioterror
prompt
develop
effect
vaccin
improv
safeti
profil
attenu
replic
smallpox
vaccin
deriv
lister
strain
vaccinia
current
licens
japan
safe
use
children
shown
markedli
less
neurotox
unattenu
vaccin
nonclin
studi
immunogen
singl
dose
recent
studi
two
differ
anim
model
demonstr
protect
efficaci
equival
fdalicens
smallpox
vaccin
articl
review
histori
avail
scientif
literatur
regard
provid
comparison
smallpox
vaccin
effort
intensifi
intern
erad
smallpox
health
offici
becam
increasingli
concern
advers
reaction
vaccinia
vaccin
offici
countri
low
incid
smallpox
particularli
alarm
morbid
mortal
associ
postvaccin
enceph
encephalopathi
central
nervou
system
cn
advers
reaction
gener
consid
idiosyncrat
event
incid
seem
vari
strain
vaccinia
observ
eventu
substanti
marennikova
group
viral
pharmaceut
institut
russia
publish
anim
data
character
commonli
use
strain
vaccinia
show
correl
degre
pathogen
viral
replic
cn
tissu
accord
marennikova
report
ikeda
strain
vaccinia
classifi
high
pathogen
wherea
lister
strain
use
world
health
organ
uk
nation
health
servic
nh
rate
medium
pathogen
new
york
citi
board
health
strain
nycbh
also
manufactur
trade
name
dryvax
use
us
rate
low
pathogen
respons
grow
concern
vacciniarel
advers
event
ae
japan
japanes
ministri
health
form
smallpox
vaccin
research
group
svrg
organ
compris
clinic
expert
basic
scientist
charg
provid
collect
detail
inform
advers
reaction
vaccinia
vaccin
advis
japanes
public
health
author
time
marennikova
report
strain
vaccinia
use
smallpox
vaccin
japan
ikeda
rate
enceph
japan
approxim
per
million
per
year
highest
risk
mortal
primari
vaccine
particularli
infant
one
first
task
svrg
investig
cn
toxic
sever
strain
vaccinia
mice
inocul
intracerebr
result
mous
studi
confirm
greater
neurotox
ikeda
strain
report
marennikova
spawn
sever
clinic
trial
children
compar
ikeda
lister
strain
use
russia
collect
data
sever
thousand
primari
vaccine
found
studi
vaccin
induc
similar
take
rate
antibodi
respons
febril
reaction
lister
mildest
local
reactogen
direct
conclus
could
made
regard
rel
neurotox
studi
vaccin
local
reactogen
time
regard
indic
overal
vaccinia
toxic
use
identifi
lister
safest
vaccin
strain
trial
svrg
recommend
routin
smallpox
vaccin
japan
conduct
use
lister
instead
ikeda
strain
reduc
vaccinerel
morbid
mortal
svrg
recommend
vaccin
initi
month
age
rather
month
punctur
administ
bifurc
needl
despit
chang
death
vaccinerel
enceph
tabl
continu
japan
geograph
risk
import
smallpox
india
svrg
reluct
discontinu
vaccin
altogeth
industri
nation
done
earli
therefor
decis
made
search
vaccin
reduc
elimin
cn
risk
search
began
review
studi
data
two
attenu
smallpox
vaccin
undergon
consider
develop
nation
modifi
vaccinia
ankara
mva
strain
develop
germani
passag
vaccinia
ankara
chick
embryo
explant
cee
excess
time
result
mutant
dramat
modifi
lost
nearli
origin
genom
well
abil
replic
mani
mammalian
cell
although
clearli
neurotox
nonclin
studi
nonreact
normal
dermatologicallyor
immunecompromis
host
antibodi
respons
follow
singl
vaccin
poor
sinc
humor
immun
respons
becom
lead
criterion
determin
vaccinia
protect
efficaci
develop
mva
vaccin
japan
abandon
anoth
attenu
strain
origin
call
first
reviv
strain
later
renam
cvi
parker
et
al
develop
us
earli
repeat
passag
nycbh
strain
rabbit
test
cee
chorioallanto
membran
cam
attenu
strain
cvi
passag
develop
kemp
et
al
walter
reed
armi
institut
research
late
ultim
select
develop
base
mild
dermatolog
reaction
produc
rabbit
human
studi
similar
result
seen
numer
clinic
studi
mild
local
reactogen
fever
without
seriou
advers
reaction
observ
addit
appear
offer
major
advantag
dermatolog
compromis
individu
kemp
et
al
confirm
safeti
vaccin
children
eczema
nevertheless
two
critic
find
dampen
enthusiasm
vaccin
first
neurotox
follow
intracerebr
inocul
monkey
shown
exceed
unattenu
ikeda
lister
nycbh
strain
suggest
greater
human
risk
enceph
second
found
immun
respons
particularli
neutral
antibodi
respons
low
compar
unattenu
lister
ikeda
strain
call
question
protect
efficaci
vaccin
svrg
ultim
decid
sponsor
develop
entir
new
attenu
strain
spearhead
dr
hashizum
chiba
serum
institut
japan
latest
technolog
understand
vaccinia
virus
coupl
develop
variant
lister
produc
neurotox
anim
model
yet
maintain
neutral
antibodi
titer
compar
lister
addit
cell
cultur
techniqu
employ
avoid
contamin
problem
inher
anim
lymphderiv
vaccin
lister
nycbh
may
contribut
toxic
allow
mass
product
control
condit
produc
new
strain
lister
initi
passag
primari
rabbit
kidney
prk
cell
low
temperatur
c
gener
clone
select
evalu
abil
grow
vero
cell
clone
lowest
titer
growth
design
lister
clone
isol
evalu
growth
rabbit
skin
cn
rabbit
monkey
compar
favor
lister
small
clinic
trial
conduct
compar
lister
children
vaccin
well
toler
reduc
fever
rate
compar
lister
howev
delay
pock
format
resolut
observ
children
vaccin
attenu
strain
lessen
chanc
autoinocul
complic
due
prolong
pock
reaction
clone
produc
small
pock
featur
correl
diminish
growth
capac
mammalian
tissu
select
cam
viru
passag
six
time
prk
low
temperatur
follow
growth
cam
mediums
mm
pock
isol
design
lister
clone
medium
pock
size
cam
origin
clone
final
clone
passag
three
time
prk
cell
grown
cam
small
mm
pock
select
final
attenu
clone
call
clone
formal
vitro
comparison
subsequ
carri
evalu
replic
capac
lister
strain
c
wherea
strain
abl
grow
c
unabl
grow
temperatur
c
clone
unabl
grow
temperatur
c
contrast
lister
grew
temperatur
test
neurotox
effect
parent
lister
strain
three
attenu
strain
assess
inocul
rabbit
strain
intracerebr
concentr
tcid
viru
rabbit
inocul
unattenu
lister
develop
enceph
wherea
none
rabbit
inocul
attenu
strain
develop
advers
neurolog
symptom
homogen
brain
rabbit
inocul
low
level
detect
viru
wherea
brain
homogen
rabbit
inocul
compar
notabl
lister
strain
contain
higher
level
viru
followup
studi
perform
cynomolgu
monkey
studi
ml
pfu
tcid
inject
intrathalam
one
monkey
group
euthan
postinject
day
evalu
cn
tissu
viru
titer
growth
cn
tissu
observ
profoundli
lower
addit
fewer
patholog
chang
observ
brain
spinal
cord
monkey
inject
evalu
abil
attenu
viru
strain
infect
tissu
beyond
skin
viru
titer
assess
blood
brain
normal
immunosuppress
cortisonetr
mice
mice
inocul
intraperiton
ip
pfu
lister
five
mice
group
sacrif
daili
evalu
viremia
cn
viral
growth
inocul
lister
strain
viru
detect
brain
day
normal
immunosuppress
anim
wherea
viru
identifi
brain
immunosuppress
anim
anim
inocul
either
strain
viru
detect
brain
either
normal
immunosuppress
anim
howev
detect
bloodstream
day
normal
mice
day
immunosuppress
mice
fig
lister
also
compar
local
reactogen
inocul
rabbit
intraderm
score
erythemat
respons
viru
produc
largest
erythemat
reaction
follow
lister
strain
final
produc
smallest
erythemat
reaction
vaccin
protect
efficaci
extrapol
rabbit
studi
measur
hemagglutinationinhibit
hi
plaqu
reduct
neutral
titer
prnt
shown
tabl
hi
prnt
respons
compar
favor
respons
lister
strain
support
clinic
evalu
suffici
dose
dose
provid
health
offici
prefectur
throughout
japan
vaccin
children
respect
practition
instruct
use
vaccin
standard
lister
vaccin
routin
primari
vaccin
children
year
predominantli
year
old
infant
includ
exclus
criteria
includ
known
congenit
acquir
heart
problem
wet
eczema
known
histori
sever
drug
allergi
sever
lister
inocul
tcid
anim
inocul
pfuanim
note
respect
unit
use
report
titer
hi
titer
done
twofold
dilut
test
sera
prnt
titer
done
fourfold
dilut
test
sera
sourc
hashizum
et
al
kidney
liver
diseas
epilepsi
immunocompromis
histori
convuls
past
year
vaccin
administ
use
approxim
l
dose
percutan
concentr
pfuml
via
bifurc
needl
punctur
upper
deltoid
region
within
larg
cohort
vaccine
children
close
evalu
local
system
reaction
take
rate
assess
day
physic
exam
perform
week
vaccin
sinc
vesicular
pustular
reaction
follow
vaccin
use
sinc
time
jenner
evid
vaccine
develop
protect
immun
take
rate
defin
vesicular
pustular
reaction
site
vaccin
local
red
indur
alon
record
nontak
data
local
system
reactogen
deriv
survey
provid
parent
guardian
vaccine
clinic
assess
object
queri
conduct
postvaccin
clinic
visit
endpoint
assess
includ
fever
system
symptom
lymphadenopathi
local
red
indur
take
rate
assess
advers
reaction
produc
take
rate
equival
smallpox
vaccin
use
japan
tabl
vaccinia
strain
maxim
advers
effect
report
around
time
peak
pock
reaction
day
postvaccin
local
indur
site
vaccin
rate
fever
peak
temperatur
fever
durat
significantli
less
lister
vaccin
close
evalu
subject
receiv
case
urticaria
case
eczema
vaccinatum
ev
case
autoinocul
case
rash
local
around
vaccin
site
benign
febril
seizur
unclear
etiolog
although
case
ev
mild
resolv
without
sequela
detail
regard
preexist
skin
condit
vaccin
child
known
sever
substudi
conduct
within
larg
clinic
trial
one
involv
remov
excess
vaccin
site
vaccin
alcohol
wipe
assess
possibl
impact
rate
autoinocul
take
rate
excess
vaccin
remov
min
postvaccin
result
show
vaccin
take
rate
high
autoinocul
rate
low
wipe
vaccin
site
within
min
contrast
vaccin
allow
dri
min
wipe
autoinocul
rate
higher
second
substudi
examin
lister
challeng
vaccin
administ
variou
timepoint
rang
day
month
postprimari
vaccin
japanes
public
health
offici
hope
vari
interv
primari
challeng
vaccin
substudi
monitor
cutan
effect
would
abl
gain
insight
speed
primari
attenu
vaccin
elicit
immun
respons
well
robust
longev
respons
shown
tabl
crossprotect
immun
lister
challeng
vaccin
induc
earli
vast
major
vaccine
find
compar
ikedadairen
result
takeuchi
report
children
year
old
vaccin
challengeinocul
lister
day
later
develop
small
pustul
remain
children
either
detect
reaction
rednessindur
scab
vaccin
site
find
suggest
crossprotect
poxvirus
variola
could
mount
quickli
follow
primari
vaccin
maintain
littl
variat
first
year
vaccin
longest
timepoint
studi
howev
studi
shown
protect
primari
reaction
follow
revaccin
although
propos
histor
purpos
definit
measur
like
protect
efficaci
relev
cutan
reaction
upon
revaccin
therefor
unclear
humor
immun
respons
month
vaccin
compar
data
gener
follow
vaccin
lister
vaccin
hi
titer
induc
four
vaccin
differ
significantli
tabl
although
number
recipi
assess
prnt
antibodi
gener
less
sampl
hi
versu
titer
follow
vaccin
appear
compar
gener
follow
lister
vaccin
superior
titer
achiev
vaccin
although
enceph
rare
observ
subject
vaccin
differ
strain
vaccinia
investig
believ
strain
potenti
induc
overt
neurotox
might
also
produc
transient
brainwav
anomali
use
electroencephalogram
eeg
predict
postvaccin
enceph
never
valid
eeg
perform
document
possibl
subclin
neurotox
cohort
children
age
vaccin
test
done
prior
vaccin
week
postvaccin
find
compar
histor
eeg
data
children
vaccin
lister
tabl
combin
clinic
immunolog
data
convinc
svrg
safe
effect
vaccin
ninetythousand
dose
vaccin
distribut
use
report
sever
ae
nevertheless
unclear
mani
dose
actual
administ
rapid
erad
smallpox
india
led
discontinu
routin
smallpox
vaccin
japan
shortli
thereaft
last
known
natur
acquir
case
smallpox
occur
africa
strain
differ
parent
lister
strain
number
biolog
characterist
summar
tabl
temperatur
sensit
due
restrict
replic
temperatur
c
rather
thermal
labil
stabil
phenotyp
cam
small
pock
size
growth
kinet
temperatur
sensit
test
confirm
repeat
passag
viru
prk
cell
regard
replic
kinet
lister
virus
essenti
singlestep
growth
curv
suggest
small
pock
size
cam
due
restrict
intracellular
replic
rather
rel
inabl
viru
spread
celltocel
analysi
lister
genom
restrict
endonucleas
crosshybrid
reveal
contain
new
restrict
site
xhoi
locat
hindiii
fragment
near
terminu
genom
recombin
studi
hindiii
fragment
lister
introduc
strain
shown
part
genom
contain
extra
xhoi
respons
small
plaqu
pock
size
restrict
growth
vero
cell
gene
fragment
origin
call
pshr
plaqu
sizehost
rang
identifi
relat
regul
complement
activ
rca
gene
famili
mammal
contain
characterist
short
consensu
repeat
scr
domain
fig
recent
analysi
full
sequenc
lister
genom
confirm
delet
gene
introduc
stop
codon
within
gene
result
fulllength
gene
encod
protein
alter
gene
theoret
would
encod
protein
process
correctli
would
secret
infect
cell
protein
orthopoxvirus
produc
four
form
viru
particl
intracellular
matur
viru
imv
intracellular
envelop
viru
iev
cellassoci
envelop
viru
cev
extracellular
envelop
viru
eev
delet
gener
result
decreas
product
eev
critic
celltocel
transmiss
viru
within
infect
host
play
import
role
diseas
pathogenesi
also
target
neutral
antibodi
antibodi
shown
protect
mice
lethal
infect
yet
recent
lethal
poxviru
challeng
studi
rabbit
mice
demonstr
delet
gene
diminish
efficaci
abil
induc
eev
antibodi
primat
studi
also
suggest
protein
critic
smallpox
vaccin
efficaci
hooper
et
al
abl
show
dryvaxvaccin
monkey
detect
neutral
antibodi
could
surviv
lethal
monkeypox
viru
challeng
serum
particular
monkey
abl
neutral
monkeypox
vvconnaught
vaccin
strain
deriv
nycbh
strain
prnt
assay
possibl
protect
confer
eev
surfac
protein
may
serv
epitop
neutral
antibodi
also
evid
smallpox
vaccin
induc
cellmedi
immun
cmi
henc
possibl
neutral
epitop
truncat
protein
might
contribut
overal
protect
immun
respons
without
primari
mediat
compar
vaccin
recent
shown
prolong
passag
cell
cultur
undergo
phenotyp
revers
character
product
plaqu
intermedi
size
wildtyp
precursor
viru
plaques
heterogen
map
gene
variant
exhibit
point
mutat
upstream
known
singlebas
delet
compensatori
mutat
correct
observ
frameshift
lead
reconstitut
fulllength
gene
western
blot
analysi
confirm
restor
abil
variant
produc
fulllength
protein
sever
combin
immunodefici
scid
mous
ld
studi
pathogen
two
revert
virus
precursor
strain
similar
addit
plaquepurifi
construct
lack
gene
shown
safeti
profil
compar
mva
anim
model
confer
protect
immun
mouseintranas
vaccinia
western
reserv
wr
strain
challeng
studi
specif
clinic
consequ
correl
delet
mutat
gene
attenu
vaccinia
strain
begin
studi
orthopoxvirus
known
use
wide
array
immunomodulatori
strategi
establish
rapid
ongo
infect
within
host
mechan
target
innat
humor
cellmedi
immun
pathway
use
mechan
divers
function
mimicri
host
protein
mask
avoid
innat
antivir
pathway
yet
known
immunomodulatori
mechan
use
alter
attenu
lister
complet
genom
sequenc
lister
virus
publish
recent
studi
underway
compar
genom
proteom
profil
group
profil
orthopoxvirus
two
group
independ
show
vaccinia
virus
could
modifi
serv
clone
express
vector
insert
foreign
dna
nonessenti
region
genom
sinc
numer
studi
demonstr
util
recombin
vaccinia
virus
rvv
effect
vector
system
due
abil
produc
robust
cellular
humor
immun
respons
carri
capac
larg
dna
fragment
rival
vector
system
eg
lentiviru
alphaviru
aav
adenoviru
rvv
may
prefer
strategi
deliveri
foreign
antigen
replicationdefici
eg
mva
replicationcompet
vector
strategi
employ
safeti
major
distinct
two
approach
sinc
fever
enceph
progress
vaccinia
myopericard
sometim
accompani
vaccin
replicationcompet
vaccin
replic
rvv
vector
system
safe
capabl
elicit
strong
immun
respons
highli
desir
attract
option
live
rvv
character
temperatur
sensit
restrict
host
rang
infrequ
lowgrad
advers
event
moreov
found
immunogen
unattenu
parent
lister
gener
prefer
vector
system
tabl
highlight
mani
tabl
histori
rvv
vector
antigen
deliveri
protein
express
modifi
updat
antigen
deliveri
protein
express
applic
use
either
vector
system
recent
abstract
show
particularli
promis
result
sar
coronaviru
sarscov
vaccin
observ
neutral
antibodi
titer
sarscov
spike
protein
increas
week
vaccin
increas
addit
week
booster
inject
interestingli
rabbit
preexist
antibodi
vector
preimmun
still
gener
antibodi
respons
suggest
vector
system
might
produc
vaccin
suitabl
popul
undergon
prior
immun
smallpox
vaccin
work
kidokoro
et
al
demonstr
vector
provid
robust
protein
express
system
preserv
function
integr
express
protein
investig
abl
obtain
yield
mgl
puriti
glycosyl
measl
viru
hemagglutinin
h
protein
base
promis
result
studi
determin
gener
util
vector
largescal
express
protein
warrant
sinc
anim
challeng
studi
conduct
develop
altern
measur
immun
use
character
smallpox
vaccin
use
evalu
efficaci
earli
clinic
trial
japan
includ
basic
antibodi
tcell
assay
monitor
cutan
respons
primari
vaccin
howev
current
standard
determin
vaccinia
efficaci
reli
sophist
measur
humor
cmi
respons
well
lethal
poxviru
challeng
vaccin
anim
model
one
exampl
latter
lethal
rabbitpox
viru
rpxv
rabbit
mimic
smallpox
infect
human
sinc
rapidli
wide
dissemin
highli
infecti
produc
high
level
eev
latter
appear
play
promin
role
pathogenesi
rpxv
variola
make
rpxv
challeng
model
particularli
suitabl
test
eevneutr
capabl
henc
protect
efficaci
recent
evalu
rabbit
model
use
rpxv
challeng
compar
studi
rabbit
per
group
vaccin
scarif
approxim
pfu
dryvax
phosphatebuff
salin
pb
placebo
day
group
divid
two
challeng
low
high
intraderm
dose
rpxv
pfu
respect
monitor
day
day
postchalleng
vaccin
anim
surviv
wherea
lowdos
challeng
highdos
challeng
placebo
pb
anim
die
fig
antibodi
respons
character
day
postvaccin
measur
abil
bind
imv
well
abil
neutral
imv
eev
rpxv
prnt
assay
antibodi
rabbit
greater
capac
bind
rpxv
elisa
data
shown
well
neutral
rpxv
imv
compar
antibodi
dryvaxvaccin
rabbit
fig
interestingli
antibodi
dryvaxvaccin
anim
show
compar
abil
neutral
rpxv
eev
fig
antibodi
respons
dryvax
rabbit
sera
obtain
rabbit
day
immun
test
dilut
neutral
imv
eev
form
rpv
plaquereduct
assay
data
point
repres
mean
serum
sampl
error
bar
indic
confid
interv
imv
neutral
titer
elicit
significantli
greater
elicit
dryvax
p
twosid
wilcoxon
rank
sum
test
sera
obtain
pbsimmun
anim
demonstr
neutral
data
shown
final
plaqu
viru
assay
use
measur
viru
differ
tissu
show
detect
rpxv
lung
liver
spleen
group
vaccin
anim
wherea
placebo
anim
high
titer
viru
organ
second
anim
model
compar
dryvax
abil
protect
ancr
mice
aerosol
ectromelia
viru
ectv
caus
agent
mousepox
model
chosen
sinc
close
mimic
rout
smallpox
might
deliv
bioterrorist
attack
ten
mice
per
group
vaccin
scarif
approxim
pfu
dryvax
pb
placebo
fortynin
day
later
anim
challeng
dose
approxim
time
lethal
dose
ld
aerosol
ectv
day
follow
challeng
vaccin
anim
surviv
wherea
placebo
mice
die
fig
signific
clinic
symptom
weight
differ
note
dryvaxvaccin
mice
postchalleng
serum
sampl
taken
mice
day
vaccin
sampl
assess
recognit
orthopoxviru
use
elisa
vaccinia
western
reserv
wr
antigen
seen
rabbit
studi
sera
mice
gener
higher
vacciniaspecif
elisa
titer
sera
dryvaxvaccin
mice
fig
rabbit
mous
data
preced
studi
agreement
recent
work
mousevaccinia
wr
intranas
challeng
model
kidokoro
et
al
report
abl
induc
prnt
antibodi
protect
lethal
challeng
equival
dryvax
report
author
determin
similar
mva
contrast
dryvax
induc
mortal
scid
mice
despit
given
dose
higher
protect
dose
particular
mous
model
fig
geometr
mean
titer
vaccinia
virusspecif
antibodi
mice
vaccin
dryvax
sera
obtain
mice
day
immun
test
vaccinia
virusspecif
antibodi
elisa
bar
repres
geometr
mean
titer
dryvaximmun
anim
anim
although
mice
vaccin
dryvax
serum
volum
anim
insuffici
analysi
error
bar
indic
confid
interv
geometr
mean
titer
elicit
significantli
greater
elicit
dryvax
p
twosid
wilcoxon
rank
sum
test
sera
obtain
pbsimmun
anim
contain
detect
vaccinia
virusspecif
antibodi
data
shown
confirm
protect
efficaci
anoth
mousevaccinia
wr
challeng
model
report
morikawa
et
al
demonstr
protect
equival
lister
vaccin
strain
final
recent
report
saijo
et
al
lister
provid
protect
diseas
monkey
challeng
sever
intranas
monkeypox
japan
retain
nation
stockpil
sinc
condit
licens
uncondit
licensur
grant
govern
decid
increas
volum
stockpil
respons
resurg
monkeypox
africa
earli
respons
terrorist
threat
us
region
world
anticip
increas
product
employe
chiba
serum
institut
manufactur
volunt
vaccin
novemb
follow
safeti
immunogen
fiftysix
revaccine
strain
date
previou
vaccin
unknown
primari
vaccine
administ
use
fivepunctur
bifurc
needl
inocul
techniqu
symptom
diari
kept
week
vaccin
site
inspect
medic
personnel
day
postvaccin
clinic
observ
record
vaccin
worker
summar
tabl
vaccin
site
symptom
mild
mostli
pruriti
resolv
within
week
phase
iii
clinic
trial
present
underway
us
evalu
safeti
immunogen
preliminari
data
recent
present
formal
publish
shortli
current
us
stockpil
smallpox
vaccin
compris
vaccin
use
nycbh
vaccinia
strain
primarili
calf
lymph
deriv
apsv
wetvax
dryvax
manufactur
earli
respect
one
recent
manufactur
cell
cultur
deriv
although
well
proven
regard
protect
efficaci
smallpox
firstgener
vaccin
dryvax
may
produc
rate
local
system
advers
reaction
unaccept
postendem
smallpox
era
particularli
given
higher
rate
immunosuppress
skin
diseas
today
popul
common
reaction
dryvax
includ
fever
lymphadenopathi
lymphaden
seriou
advers
event
includ
autocontact
inocul
gener
vaccinia
eczema
vaccinatum
progress
vaccinia
enceph
concern
also
express
possibl
presenc
adventiti
agent
stockpil
dryvax
apsv
sinc
calf
lymphperpetu
smallpox
vaccin
screen
mycoplasma
virus
prion
manufactur
death
dryvax
vaccin
us
prior
erad
smallpox
frequent
due
enceph
occur
rate
approxim
one
per
million
primari
vaccine
recent
clinic
trial
evalu
dryvax
myopericard
seriou
advers
event
rare
report
past
found
occur
high
rate
among
primari
vaccine
care
evalu
vaccine
clinic
subclin
symptom
reaction
identifi
primari
vaccine
prompt
addit
black
box
warn
packag
insert
dryvax
discoveri
fuel
drive
identifi
smallpox
vaccin
improv
safeti
profil
initi
attempt
improv
vaccin
safeti
focus
modern
manufactur
dryvax
grow
viru
cell
cultur
clone
singl
subpopul
strain
nycbh
character
protect
efficaci
low
neurovirul
anim
studi
clinic
trial
acambisproduc
secondgener
nycbh
vaccin
deriv
grown
vero
cell
rather
cell
confirm
high
take
rate
immunogen
qualiti
progress
time
pock
reaction
similar
seen
dryvax
control
local
system
reaction
apart
local
reaction
inject
site
common
advers
reaction
lymph
node
axillari
pain
seen
primari
vaccine
unfortun
subclin
overt
myopericard
also
found
occur
high
rate
dryvax
control
group
addit
one
vaccine
given
experiment
vaccin
experienc
new
onset
seizur
day
postvaccin
anoth
recent
phase
ii
studi
myopericard
develop
one
subject
day
vaccin
pfuml
ccsv
cellcultur
smallpox
vaccin
version
nycbh
vaccinia
strain
grown
cell
dynport
vaccin
compani
dvc
recent
evalu
doubleblind
dryvaxcontrol
clinic
trial
conduct
vaccinia
naiv
nonnaiv
volunt
acambi
product
rate
advers
reaction
ccsv
similar
dryvax
howev
seriou
advers
reaction
myopericard
report
trial
ccsvinduc
prnt
titer
seroconvers
rate
gener
lower
induc
dryvax
given
disappoint
safeti
find
cell
culturederiv
secondgener
vaccin
focu
shift
thirdgener
vaccin
mva
imvamun
bavarian
nordic
acambi
potenti
mean
replenish
nation
stockpil
japanes
govern
recent
announc
significantli
expand
nation
stockpil
afford
protect
million
peopl
event
bioterrorist
attack
mva
extens
histori
safeti
human
peopl
vaccin
germani
although
singl
dose
approxim
pfu
present
reassess
variou
clinic
nonclin
studi
although
rational
use
nonrepl
vaccin
highrisk
popul
immunosuppress
skin
diseas
compel
efficaci
smallpox
unknown
nonclin
studi
evalu
protect
efficaci
mva
indic
multipledos
regimen
use
higher
concentr
approxim
pfu
requir
one
studi
mice
challeng
intraderm
intranas
replic
vaccinia
protect
efficaci
observ
two
three
dose
mva
administ
current
smallpox
vaccin
investig
attenu
abl
replic
human
potenti
offer
protect
singl
dose
avail
clinic
nonclin
data
suggest
merit
studi
potenti
vaccin
use
futur
howev
develop
new
smallpox
vaccin
complic
evolv
natur
field
clear
histor
data
protect
antibodi
titer
smallpox
erad
era
reli
upon
smallpox
longer
endem
diseas
vaccin
efficaci
infer
anim
challeng
studi
correspond
immun
respons
human
us
fda
publish
specif
requir
proof
efficaci
anim
model
everi
new
smallpox
vaccin
must
meet
socal
anim
rule
given
multifactori
natur
immun
respons
smallpox
vaccin
variou
marker
humor
cellular
immun
studi
aim
identifi
object
measur
efficaci
correl
protect
human
yet
defin
unequivoc
may
reli
part
elicit
neutral
antibodi
respons
correspond
demonstr
efficaci
anim
model
although
threshold
titer
neutral
antibodi
need
protect
unknown
recent
shown
human
vacciniaspecif
antibodi
passiv
transfer
nonimmun
macaqu
offer
protect
lethal
monkeypox
challeng
lack
publish
data
vari
reagent
use
plaqu
viru
assay
make
comparison
absolut
prnt
titer
elicit
differ
smallpox
vaccin
difficult
howev
publish
result
suggest
cellcultur
nycbh
vaccin
produc
immun
respons
similar
dryvax
recent
data
prnt
level
elicit
mva
human
publish
find
forthcom
ongo
clinic
trial
durat
humor
cellmedi
protect
immun
afford
smallpox
vaccin
remain
unknown
yet
empir
experiment
evid
degre
immun
smallpox
persist
sever
decad
postvaccin
addit
hammarlund
colleagu
recent
report
smallpox
vaccin
much
year
preexposur
confer
immun
human
expos
monkeypox
data
durat
longterm
immun
current
avail
howev
immun
durat
import
consider
new
smallpox
vaccin
candid
biodefensefocus
quest
safe
effect
smallpox
vaccin
urgent
eventu
outcom
control
clinic
nonclin
studi
new
smallpox
vaccin
candid
ensur
suitabl
use
human
smallpox
recur
futur
